PharmaVOICE - 
November 2001
Purchase Issue

In Every Issue
Talent Pool
business operation functions and reports to TPNA President Alan MacKenzie. [...]
By
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES Free drug [...]
By
What’s New
In a move to solidify its commitment to multicul tural [...]
By
PharmaTrax
Aging female population presents NEW CHALLENGES in HRT MARKET The [...]
By
For Art’s Sake
Creative Review Wow! If a picture could say a zillion words, [...]
By
PharmaOutlet
Brand is not a color or a single image or [...]
By

Mike Myers and Guy Mastrion

What’s on Your Mind: Opinions
Is a fee based appointment plan a reasonable strategy? In [...]
By
Raise Your Voice: Letters
RAISE your voice Great article. It reminds me that it [...]
By
Letter from the Editor
America’s pharmaceutical industry is helping the process of healing the [...]
By

Taren Grom, Editor

On The Cover

Information Technology: Tracking the E-Volution
Pharmaceutical companies have long term plans, they have products that take a long time to develop, a long time to test to gain approval, and they have a shelf life. But technology moves so much faster than that. So the industry as a whole has had to adopt to the speed of technology. IAN CROSS [...]
By

Taren Grom, Editor

Features

Joe Krivulka: A Reliable Guy
Joe Krivulka Small opportunities are turning into big business for Joe Krivulka and Reliant Pharmaceuticals LLC, the company he cofounded just two years ago. Mr. Krivulka is seizing the opportunity to breathe new life into products being cast off by the pharmaceutical giants. “Big pharma has products that are doing 0 million to 0 million [...]
By

Kim Ribbink

A Therapeutic Path to Success
The marketers of Cox2 antiinflammatory drugs, have enjoyed two years of recordbreaking sales, but with new products poised to come to market, the challenge will be to hold onto their strong positions. Cox2 inhibitors entered the market with a splash with the launch of Celebrex in 1998. The Pharmacia/Pfizer comarketed arthritis pain med ication is [...]
By

Virginia Kirk

The Toll of Terror
was never going to be a stellar year for global economies, but until September 11, 2001, many in the business world predicted a quick recovery. Those hopes have faded somewhat as consumer spending, rising unemployment, and business uncertain ty plague some sectors. The biopharmaceuti cal industry will emerge relatively unscathed compared with other industrial sectors, [...]
By
Middle Markets
Blockbuster drugs are sexy, exciting, and they generate widespread attention. They monopolize the advertising budgets of their marketers and developers, who work to ensure that their attributes are seen by millions of consumers via television and in magazines. As a result of the Herculean promotional efforts of marketing powerhouses such as Pfizer, Merck & Co., [...]
By

Deborah Ruriani

The Practice of Public Relations
When effectively managed, public relations creates unique opportunities for marketers to provide con sumers and healthcare professionals with immediate and thorough drug and healthcare information. The healthcare publicrelations market in the United States grew 30% last year and is now valued at 4 million, with about 76% dedicated to pharmaceuticals and device and diagnostics. It [...]
By

Lynda Sears

Medical Privacy: At What Cost
By Denise Myshko WHILE QUESTIONS REMAIN ABOUT WHAT THIS ULTIMATELY WILL MEAN FOR CLINICAL RESEARCH AND THE INDUSTRY’S ACCESS TO DATA,ONE THING IS CERTAIN: AN EXTRA LAYER OF ADMINISTRATION HAS BEEN ADDED FOR EVERYONE. Privacy has become a political hot potato in the healthcare industry as advances in technology have fueled fierce debate over medical [...]
By

Denise Myshko

FEEDBACK